HopeStage
Back to all studies
CompletedNCT00167154

Risperidone added to antidepressants for suicidal thoughts in major depression

About this title

Risperidone and Suicidality in Major Depressive Disorder

Read the official source — NCT00167154
Medication studyAges 19–60United States
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 19 years to 60 years. Other eligibility criteria applied.

Listed locations
BirminghamSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2004
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
University of Alabama at Birmingham
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 19 Years to 60 Years
Official registry ID
NCT00167154
Official title
Show the full official title

Efficacy of Risperidone in the Management of Suicidality in Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Alabama at Birmingham, a university.

Did this study involve medication?

Yes. The study involved medication, including Risperidone and placebo comparator.

Who was this study for?

This study was for people with depression. Listed age limits: 19 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies